Cargando…
A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
PURPOSE: BEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K pathway. This was an open-label, multicenter, dose-escalation, phase I study of single-agent BEZ235 in Japanese oncology patients to determine th...
Autores principales: | Toyoda, Masanori, Watanabe, Koichiro, Amagasaki, Taro, Natsume, Kazuto, Takeuchi, Hiromi, Quadt, Cornelia, Shirao, Kuniaki, Minami, Hironobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394493/ https://www.ncbi.nlm.nih.gov/pubmed/30446785 http://dx.doi.org/10.1007/s00280-018-3725-2 |
Ejemplares similares
-
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019) -
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017) -
Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015) -
BEZ235: When Promising Science Meets Clinical Reality
por: Pongas, Georgios, et al.
Publicado: (2016) -
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016)